Although trastuzumab has also been viewed as a promising targeting agent for HER2-positive SCLC7, 22, there has been no preclinical or clinical reports of trastuzumab-based therapy for SCLC. The gene discussed is ERBB2; the disease is small cell lung carcinoma.